Recently, Novo Nordisk announced plans to invest up to $1.09 billion (approximately 6 billion Danish kroner) in the expansion of its existing facility in Monte Mor, Brazil. The new production site will primarily focus on the company’s core products: the GLP-1 diabetes drug Ozempic and the weight-loss drug Wegovy.
According to the company’s plan, the facility is expected to be completed by 2028 and will create over 500 high-skilled jobs. This investment is considered one of the largest pharmaceutical investments in Brazilian history. The funds will be used to introduce advanced aseptic manufacturing processes, expand warehouse capacity, and build new high-quality control laboratories. This large-scale expansion highlights Novo Nordisk’s commitment to the Brazilian market and its continued strategic push into Latin America.
This investment comes at a time when Brazilian pharmaceutical companies, such as Hypera, are preparing to enter the growing GLP-1 market. Hypera recently announced plans to launch a generic version of Ozempic once its patent expires in Brazil. Novo Nordisk stated that it is not concerned about the patent expiration, describing it as a normal part of the industry.
The global trade war initiated by former U.S. President Donald Trump will not affect this facility, as the United States is not the destination for products manufactured in Brazil. Moreover, Novo Nordisk is also separately expanding its production capabilities in the U.S.
